A detailed history of Squarepoint Ops LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 109,000 shares of CTMX stock, worth $115,540. This represents 0.0% of its overall portfolio holdings.

Number of Shares
109,000
Previous 198,840 45.18%
Holding current value
$115,540
Previous $242,000 47.11%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.21 - $5.13 $13,686 - $58,025
-11,311 Reduced 5.38%
198,840 $242,000
Q1 2024

May 15, 2024

BUY
$1.41 - $2.74 $84,061 - $163,353
59,618 Added 39.6%
210,151 $458,000
Q4 2023

Feb 14, 2024

SELL
$1.07 - $1.55 $36,338 - $52,639
-33,961 Reduced 18.41%
150,533 $233,000
Q2 2023

Aug 14, 2023

BUY
$1.41 - $1.92 $191,249 - $260,424
135,638 Added 277.63%
184,494 $317,000
Q1 2023

May 15, 2023

BUY
$1.48 - $2.88 $72,306 - $140,705
48,856 New
48,856 $73,000
Q3 2022

Nov 14, 2022

SELL
$1.23 - $1.97 $44,476 - $71,235
-36,160 Reduced 77.46%
10,523 $15,000
Q2 2022

Aug 15, 2022

SELL
$1.53 - $2.89 $91,919 - $173,625
-60,078 Reduced 56.27%
46,683 $85,000
Q1 2022

May 16, 2022

BUY
$2.67 - $4.68 $183,728 - $322,040
68,812 Added 181.33%
106,761 $285,000
Q4 2021

Feb 14, 2022

SELL
$3.87 - $7.39 $6,846 - $13,072
-1,769 Reduced 4.45%
37,949 $164,000
Q3 2021

Nov 15, 2021

SELL
$4.32 - $6.43 $3.06 Million - $4.56 Million
-708,569 Reduced 94.69%
39,718 $202,000
Q2 2021

Aug 16, 2021

BUY
$6.33 - $9.91 $4.22 Million - $6.61 Million
666,574 Added 815.75%
748,287 $4.74 Million
Q1 2021

May 17, 2021

BUY
$6.6 - $9.0 $32,373 - $44,145
4,905 Added 6.39%
81,713 $632,000
Q4 2020

Feb 16, 2021

BUY
$6.47 - $7.9 $246,280 - $300,713
38,065 Added 98.25%
76,808 $503,000
Q3 2020

Nov 16, 2020

SELL
$6.55 - $8.83 $503,832 - $679,212
-76,921 Reduced 66.5%
38,743 $258,000
Q2 2020

Aug 14, 2020

BUY
$7.4 - $14.64 $765,700 - $1.51 Million
103,473 Added 848.77%
115,664 $963,000
Q1 2020

May 15, 2020

SELL
$3.61 - $8.6 $492,266 - $1.17 Million
-136,362 Reduced 91.79%
12,191 $94,000
Q4 2019

Feb 14, 2020

SELL
$5.17 - $8.91 $271,171 - $467,338
-52,451 Reduced 26.09%
148,553 $1.23 Million
Q3 2019

Nov 14, 2019

BUY
$7.38 - $12.25 $784,346 - $1.3 Million
106,280 Added 112.2%
201,004 $1.48 Million
Q2 2019

Aug 14, 2019

SELL
$9.35 - $11.41 $393,298 - $479,950
-42,064 Reduced 30.75%
94,724 $1.06 Million
Q1 2019

May 15, 2019

BUY
$9.5 - $19.16 $541,538 - $1.09 Million
57,004 Added 71.45%
136,788 $1.47 Million
Q4 2018

Feb 14, 2019

SELL
$12.69 - $18.61 $125,364 - $183,848
-9,879 Reduced 11.02%
79,784 $1.21 Million
Q3 2018

Nov 14, 2018

BUY
$18.04 - $26.41 $436,405 - $638,884
24,191 Added 36.95%
89,663 $1.66 Million
Q2 2018

Aug 14, 2018

BUY
$21.38 - $29.68 $836,471 - $1.16 Million
39,124 Added 148.49%
65,472 $1.5 Million
Q1 2018

May 15, 2018

BUY
$21.76 - $34.22 $76,399 - $120,146
3,511 Added 15.37%
26,348 $750,000
Q4 2017

Feb 14, 2018

BUY
$19.0 - $23.09 $183,103 - $222,518
9,637 Added 73.01%
22,837 $482,000
Q3 2017

Nov 14, 2017

BUY
$13.53 - $18.17 $178,596 - $239,844
13,200
13,200 $240,000

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $69.9M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.